Chrysos Corporation (C79) investor relations material

Executive summary

• Achieved unaudited FY25 revenue of $66.1M, up 46% year-over-year, and EBITDA of $16.1M, up 80% year-over-year, driven by global adoption of PhotonAssay technology and major contracts with Newmont and Bureau Veritas.

• Deployed 11 new PhotonAssay units in FY25, totaling 40 units in operation and 59 contracted units, with expansion into South America and partnerships with all four major global laboratory companies.

• Maintained strong liquidity with $91.1M–$99.1M in cash and undrawn debt, supporting further expansion and R&D.

• Operating cash flow positive with $8.8M net inflow, enabling reinvestment and growth.

• Engaged 70% of the world's top 20 gold miners and expanded customer base through strategic agreements.

Financial highlights

• Revenue increased 46% year-over-year to $66.1M, exceeding guidance midpoint, with international revenue accounting for 65% of total.

• EBITDA grew 80% to $16.1M, with margin rising to 24% from 20% in FY24.

• Net operating cash flow of $8.8M for FY25.

• $91.1M available liquidity at year-end, including cash and undrawn debt facility.

• FY26 guidance: revenue of $80M–$90M, EBITDA of $20M–$27M.

Outlook and guidance

• FY26 guidance assumes current levels of additional assay charges and minimum monthly assay payments, with upside if industry activity accelerates.

• Nine units ready for near-term deployment, supporting continued growth and global expansion.

• Expansion into South America and new technology rollouts expected to drive further growth.

• Cautiously optimistic on industry cycle improvement, but not factored into guidance.

• Focus on expanding market share beyond current ~5% penetration.